Pioneering next-generation exosome therapeutics  ·  Explore Our Science →
Home  /  Pipeline

Pipeline
Platform-Driven Exosome Therapeutics Pipeline

P.S.K Biosciences is advancing a platform-driven exosome therapeutics pipeline built on two complementary technology platforms.

P.S.K Biosciences is advancing a platform-driven exosome therapeutics pipeline built on two complementary technology platforms: the engineered exosome RNA delivery platform and the function-defined natural exosome therapeutics platform.

Our engineered exosome platform is designed to enable systemic CNS and extrahepatic RNA delivery, supporting therapeutic programs in genetically and molecularly defined neurological diseases.

Our natural exosome platform generates function-defined MSC-derived exosome subpopulations, including S1 for inflammation modulation and S2 for regenerative and neuro-supportive applications.

Together, these platforms support a diversified pipeline across CNS disorders, inflammatory diseases, pulmonary diseases, cardiovascular injury, and regenerative medicine.

Full Pipeline

Therapeutic Programs & Development Stage

Platform Indications Discovery Preclinical Early Clinical Validation IND-enabling Clinical Commercial
CNS RNA Delivery
Huntington’s disease (HD)
Functional Exosome Therapeutics
Rapidly Progressive Interstitial Lung Disease (RP-ILD)
Acute Exacerbation of COPD (AE-COPD)

Beyond the Core Pipeline: Partnering-Ready Assets

A dual-platform portfolio spanning delivery tools and therapeutic products for licensing, co-development and strategic collaboration.

SELECT ASSETS AVAILABLE FOR PARTNERING

Engineered Exosome Delivery Platform (SGRL-Exo™)

Overcoming tissue targeting and barrier-crossing bottlenecks for nucleic acid medicines.

Brain-Targeted Delivery

Small RNA and mRNA payloads | ALS, AD and other CNS diseases

Lung-Targeted Delivery

Nucleic acid payloads | respiratory indication expansion

In Vivo CAR-T Enablement

Targeted mRNA delivery | in vivo immune-cell reprogramming

Expansion Directions

mRNA vaccines | additional RNA cargo delivery applications

Functional Natural Exosome Therapeutics Platform

Function-defined hUCMSC-exo subpopulations enabling differentiated S1/S2 programs.

S1 Subpopulation | Anti-inflammatory & Immunomodulatory

IBD; clinical study experience and multi-indication validation foundation.

S2 Subpopulation | Tissue Protection & Repair

Stroke, AD, PD, heart failure, burns, CLI and POI; selected indications suitable for co-development.

Core value: Functional subtyping enables product differentiation and indication-specific matching.

Collaboration Models

Strategic Licensing  ·  Co-development  ·  Regional / Global Development  ·  Platform Access

Spotlight

RP-ILD — Encouraging Patient Outcomes

A 10-patient IIT cohort in anti-MDA5-positive dermatomyositis-associated RP-ILD showed a 10% mortality rate, substantially lower than the historically reported mortality rate of 50–90%. Ten patients were discharged approximately two weeks after administration and remained stable during the three-month follow-up. Published clinical milestone for S1-sEVs.

10%
Mortality in PSK-treated cohort
50–90%
Historical mortality rate
9/10
Stable during the three-month follow-up.
Partner With Us

Partner With P.S.K Biosciences

We welcome strategic collaborations with pharmaceutical companies, biotech innovators, academic institutions, clinical centers, and regional development partners.

Explore Partnership Opportunities